Oncology Unit, Department of Clinical and Biological Sciences, University of Torino, San Luigi di Orbassano, Italy.
Oncologist. 2012;17(11):1430-8. doi: 10.1634/theoncologist.2012-0142. Epub 2012 Sep 6.
The role of surgery for lung metastases (LM) secondary to colorectal cancer (CRC) remains controversial. The bulk of evidence is derived from single surgical series, hampering any definitive conclusions. The aim of this study was to compare the outcomes of CRC patients with LM submitted to surgery with those who were not.
Data from 409 patients with LM as the first evidence of advanced disease were extracted from a database of 1,411 patients. Patients were divided into three groups: G1, comprised of 155 patients with pulmonary and extrapulmonary metastases; G2, comprised of 104 patients with LM only and no surgery; G3, comprised of 50 patients with LM only and submitted to surgery.
No difference in response rates emerged between G1 and G2. Median progression-free survival (PFS) times were: 10.3 months, 10.5 months, and 26.2 months for G1, G2, and G3, respectively. No difference in PFS times was observed between G1 and G2, whereas there was a statistically significant difference between G2 and G3. Median overall survival times were 24.2 months, 31.5 months, and 72.4 months, respectively. Survival times were longer in resected patients: 17 survived >5 years and three survived >10 years. In patients with LM only and no surgery, four survived for 5 years and none survived >10 years.
Even though patients with resectable LM are more likely to be those with a better outcome, our study provides evidence suggesting an active role of surgery in improving survival outcomes in this patient subset.
结直肠癌(CRC)继发肺转移(LM)的手术治疗作用仍存在争议。大部分证据来自于单一的手术系列,难以得出任何明确的结论。本研究的目的是比较接受手术治疗和未接受手术治疗的 CRC 伴 LM 患者的结局。
从 1411 例患者的数据库中提取了 409 例 LM 作为晚期疾病首发证据的患者数据。患者被分为三组:G1 组由 155 例伴肺外转移的患者组成;G2 组由 104 例仅伴 LM 且未行手术的患者组成;G3 组由 50 例仅伴 LM 且行手术的患者组成。
G1 组和 G2 组的缓解率无差异。G1、G2 和 G3 组的中位无进展生存期(PFS)分别为 10.3、10.5 和 26.2 个月。G1 组和 G2 组的 PFS 时间无差异,而 G2 组和 G3 组之间存在统计学差异。G1、G2 和 G3 组的中位总生存期分别为 24.2、31.5 和 72.4 个月。手术患者的生存时间更长:17 例患者生存时间>5 年,3 例患者生存时间>10 年。在仅伴 LM 且未行手术的患者中,4 例患者生存时间>5 年,无患者生存时间>10 年。
尽管可切除 LM 患者更有可能获得较好的预后,但本研究提供的证据表明,手术在改善该患者亚组的生存结局方面具有积极作用。